[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"topical-administration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:topical-administration":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,83,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100625706","phase-3-efficacy-and-safety-of-a-botanical-total-coumarin-tc-cream-in-treating-patients-with-psoriasis-vulgaris-plantcoat-iii-100625706",false,"NCT07426120","Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)","A Double-blind, Randomized, Placebo-controlled, Parallel-controlled, Multi-center Phase III Clinical Trial to Evaluate the Efficacy and Safety of a Botanical Total Coumarin Cream (TC Cream) in Treating Patients With Psoriasis Vulgaris","PLANTCOAT-III","Inclusion Criteria:\n\n* Age of 18-70 years old. Both men and women, and members of all races and ethnic groups\n* Consistent with the diagnostic criteria of stable phase psoriasis vulgaris, and have at least two target lesions suitable for evaluation\n* Women of childbearing age must be using birth control strategies defined by one of the following: 1) a barrier method (condom) and\u002For 2) oral contraceptives, during the 8-week study period.\n* ISGA score ≥ 2 (at least mild severity)\n* BSA (stable stage group): 1%≤ to ≤20%\n* Signed a written informed consent document\n* No additional exposure to the sun\n\nExclusion Criteria:\n\n* Subjects in pregnancy, preparing for pregnancy, or breastfeeding\n* History of hyperergic or photosensitivity\n* History of complicated cardiovascular diseases, cerebrovascular diseases, severe primary diseases of the hepatic, kidney, and hematopoietic system, or patients with psychiatric disorders\n* History of photosensitive diseases such as porphyria, chronic actinic dermatitis, Xeroderma pigmentosa\n* Within 4 weeks prior to randomization, patients have taken treatment with the following approved or investigational psoriasis therapies on the target lesions:\n\n  * Topical treatments\n  * PUVA, UVB, or Grenz ray therapy.\n  * Any systemic treatments other than biologicals with a possible effect on psoriasis (e.g., corticosteroids, vitamin D analogues, hydroxycarbamide, azathioprine, methotrexate, cyclosporine, other immunosuppressants).\n  * Any types of other investigational therapies for psoriasis\n* Within 3 months prior to randomizations, patients have taken systemic treatments with retinoids or biological therapies (marketed or otherwise) with a possible effect on psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab).\n* Planned initiation of, or changes to, concomitant medications that could affect psoriasis (e.g., beta blockers, anti-malaria drugs, lithium) during the double-blind phase of the study.\n* History of allergic reactions attributed to compounds of similar chemical or biologic compositions to Coumarins.","ALL","18 Years","70 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The goal of this clinical trial is to learn if a botanical Total Coumarin topical cream (TC Cream) works to treat psoriasis in adults. It will also learn about the safety of the topical TC Cream. The main questions it aims to answer are:\n\n* Does TC Cream improve the psoriasis disease symptoms?\n* What medical problems do participants have when applying TC Cream?\n* Does TC Cream improve the quality of life of psoriasis patients? Researchers will compare TC Cream to a placebo cream (a look-alike cream that contains no active drug) to see if TC Cream works to treat psoriasis.\n\nParticipants will:\n\n* Topically apply the TC Cream or a placebo cream twice daily every day to affected skin for 8 weeks\n* Visit the clinic once every 2 weeks for checkups and tests\n* Keep a diary of their symptoms and their diseased skin conditions during the application of the topical cream",[28,29,30],"Psoriasis Vulgaris","Topical Administration","Phase III",[32,33,34,35,36],"Psoriasis","Topical cream","Botanical drug","FDA IND","NMPA approval","RECRUITING","2026-02-15",{"date":40,"type":41},"2026-02-23","ACTUAL",{"date":43,"type":41},"2026-02-01",{"date":45,"type":22},"2028-06-30",{"name":47,"class":48},"Psoriasis Research Institute of Guangzhou","INDUSTRY",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":49},"100615690","topical-nifedipine-03-plus-lidocaine-15-for-uncomplicated-hemorrhoidal-disease-100615690","NCT07295886","Topical Nifedipine 0.3% Plus Lidocaine 1.5% for Uncomplicated Hemorrhoidal Disease","Observational Study on the Use of Topical Nifedipine 0.3% and Lidocaine 1.5% in Acute Uncomplicated Hemorrhoidal Disease","NILOS","Inclusion Criteria:\n\n* Male and female patients aged 18-75 years.\n* Clinical or anoscopic diagnosis of acute hemorrhoidal disease with prolapse severity between Grade II and IV (Goligher), possibly associated with external congestion.\n* Patients who started treatment with nifedipine 0.3% + lidocaine 1.5% within the past 5 days.\n* Availability of clinical evaluations at treatment initiation (proctologic visit and HDSS, SHS-HD, VAS scales).\n* Ability to understand the informed consent.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Acute hemorrhoidal disease complicated by thrombosis or strangulation.\n* Coagulopathies.\n* Active neoplastic disease.\n* Treatment with anticoagulants and\u002For chemotherapeutic agents.\n* Hypersensitivity to active substances, especially lidocaine (and other amide-type local anesthetics) or excipients.\n* Severe hypotensive states or cardiovascular insufficiency.\n* Pregnancy or breastfeeding.\n* Participation in clinical trials involving investigational drugs.","75 Years",{"count":60,"type":22},80,"30 Days","OBSERVATIONAL","The goal of this observational study is to evaluate the effectiveness of topical nifedipine 0.3% plus lidocaine 1.5% for uncomplicated hemorrhoidal disease. The main question it aims to answer is:\n\nDoes topical nifedipine 0.3% plus lidocaine 1.5% lower symptoms in patients with uncomplicated acute hemorrhoidal disease? Participants already taking nifedipine 0.3% plus lidocaine 1.5% as part of their regular medical care for hemorrhoidal disease will undergo four visits over a 30-day period, including two telephone contacts and two in-person visits.",[65,66,67,68,29],"Hemorrhoid Bleeding","Hemorrhoids Prolapse","Hemorrhoid Pain","Hemorrhoid",[70,71,72],"nifedipine 0.3% plus lidocaine 1.5%","uncomplicated hemorrhoidal disease","hemorrhoids symptoms","2025-12-19",{"date":75,"type":41},"2025-12-22",{"date":77,"type":41},"2025-09-02",{"date":79,"type":22},"2026-05-02",{"name":81,"class":82},"Cardarelli Hospital","OTHER",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100573834","phase-1-evaluation-of-clinical-perceived-and-instrumental-efficacy-of-a-scar-gel-in-preventing-hypertrophic-scars-100573834","NCT06751433","Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel in Preventing Hypertrophic Scars","Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel Versus Benchmark in Preventing Hypertrophic Scars and Improving Scar Appearance","Inclusion Criteria:\n\n1. Participants of both sexes aged between 18 and 70 years;\n2. Participants with recent scars (\\\u003C30 days);\n3. Participants with phototypes III to VI according to the Fitzpatrick scale;\n4. Agree to follow the trial procedures and attend the center on the days and times determined for evaluations;\n5. Understand, agree to and sign the free and informed consent form.\n6. Types of scars: cesarean section, breast implant or blunt cut injury.\n\nExclusion Criteria:\n\n1. Pregnancy or risk of pregnancy;\n2. History of atopic or allergic reactions to cosmetic products;\n3. Participants who are using topical antibiotics or other skin products on the same area being evaluated;\n4. Immunosuppression due to drugs or active diseases;\n5. Decompensated endocrine diseases;\n6. Relevant clinical history or current evidence of alcohol or other drug abuse;\n7. Known history or suspected intolerance to products in the same category;\n8. Intense sun exposure up to 15 days before the evaluation;\n9. Patients who are using topical antibiotics or other skin products on the same area being evaluated.",{"count":60,"type":22},[92,93],"PHASE1","PHASE2","Evaluation of the safety and topical efficacy of a scar gel after 90 days of continuous use, comparing it to a benchmark for preventing hypertrophic scars and improving appearance, hydration and pigmentation.",[96,97,98,29,99,100],"Acceptability Study","Real-use Conditions","Safety and Efficacy","Hypertrophic Scars","Keloid Scars","2025-09-09",{"date":103,"type":41},"2025-09-11",{"date":105,"type":41},"2025-04-03",{"date":107,"type":22},"2025-12",{"name":109,"class":48},"Herbarium Laboratorio Botanico Ltda",2,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":123,"conditions":124,"keywords":127,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":49},"100604456","phase-1-pilot-study-miltefosine-gel-g-mtf-in-patients-with-cutaneous-leishmaniasis-100604456","NCT07149753","Pilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis","Pilot Study: Safety and Therapeutic Dose of a Miltefosine Gel (G-MTF) in Patients With Uncomplicated Cutaneous Leishmaniasis (NCCL)","G-MTF01","Inclusion Criteria:\n\n* Diagnosis of confirmed cutaneous leishmaniasis (CL)\n* Age: 18 - 65 years.\n* Patients who have 1-4 CL skin lesions with a diameter of 1-4 cm, with an evolution time of more than one month and not located on the face, ears, or joints.\n* Patients WITHOUT suspected complicated CL (large regional lymphadenopathy, several large lesions spread to different parts of the body); NO mucosal leishmaniasis and NO suspicion of unusual leishmaniasis syndromes (e.g., recurrent leishmaniasis, diffuse or disseminated CL).\n* Patients with NO history of systemic antileishmania treatment within 8 weeks prior to starting the study.\n* Patients WITHOUT treatment failure with local therapy (intralesional antimonial injections or thermotherapy) or systemic therapy.\n\nExclusion Criteria:\n\n* Pregnant or lactating women; women of reproductive age who refuse to use contraception until 45 days after treatment ends.\n* Patients with cardiovascular, hepatic, or renal impairment or who report underlying diseases that medically compromise their participation in this study.\n* Patients who report a history of immunodeficiency.","65 Years",{"count":121,"type":22},15,[92],"The goal of this clinical trial is to learn if the drug MILTEFOSINE, used topically in a hydrogel, works to treat non-complicated cutaneous leishmaniasis (CL) in adults. It will also learn about the safety of the drug MILTEFOSINE used topically. The main questions it aims to answer are:\n\n* Is topical treatment with MILTEFOSINE hydrogel effective in patients with CL, thus justifying its continuation in the clinical phases (II and III) of development?\n* What skin problems do participants have when using miltefosine hydrogels over CL lesions? Researchers will evaluate the safety and effectiveness of various concentrations of MILTEFOSINE hydrogel: 0.5%, 1.0%, and 1.5%.\n\nParticipants will:\n\n* Apply the MILTEFOSINE hydrogel to the affected lesions daily for 28 consecutive days.\n* Visit the Center at least two days prior to the study. This initial visit will include diagnostic tests, interviews, study information, informed consent, and the administration of the first doses. After this, patients are required to return to the clinic on day 28 and again three months later for additional check-ups and tests.\n* Take a photo once a week for checkups, and keep a note of their symptoms",[125,126,29],"Cutaneous Leishmaniasis","Cutaneous Leishmaniasis, American",[128,129,130,131],"cutaneous leishmaniasis","topical treatment","miltefosine","hydrogel","NOT_YET_RECRUITING","2025-08-30",{"date":135,"type":41},"2025-09-08",{"date":137,"type":22},"2026-01-01",{"date":139,"type":22},"2026-08-30",{"name":141,"class":82},"Universidad Industrial de Santander"]